OraSure Technologies (NASDAQ:OSUR) Posts Quarterly Earnings Results

OraSure Technologies (NASDAQ:OSUR) issued its earnings results on Monday. The medical instruments supplier reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05, FiscalAI reports. The company had revenue of $30.91 million during the quarter, compared to analysts’ expectations of $31.00 million. OraSure Technologies had a negative net margin of 43.70% and a negative return on equity of 19.09%.

Here are the key takeaways from OraSure Technologies’ conference call:

• Q3 revenue grew 14% year over year to $30.9 million, while gross margin expanded 173 basis points to 45.2% and operating expenses declined. OraSure expects full-year 2026 revenue of $119.5 million to $121.5 million, implying growth of 3.8% to 5.6%.
• Both major portfolios grew, with diagnostics revenue up 16% and sample management solutions up 21% year over year. OraSure cited early Colli-Pee sales and continued demand for U.S. HIV, HCV, and syphilis testing, while saying new products should contribute to faster growth in 2027.
• The company now expects to reach operating cash flow breakeven in the second half of 2027, later than its prior goal of breakeven entering 2027, as the timing and mix of growth opportunities changed.
• Ebola testing commercialization remains dependent on pending study results and evolving country-specific evaluation and procurement processes. OraSure has fulfilled initial orders and expects further contracting before year-end, but did not provide sales estimates or a firm timeline for broader adoption.
• The regulatory path for OraQuick InteliQuick CT/NG remains uncertain after the company withdrew its FDA submission in August. OraSure is in pre-submission discussions to determine a resubmission pathway, with timing and potential costs still unclear.

OraSure Technologies Stock Up 2.6%

Shares of OSUR opened at $3.53 on Tuesday. OraSure Technologies has a twelve month low of $2.08 and a twelve month high of $4.58. The stock has a market capitalization of $243.46 million, a P/E ratio of -5.12 and a beta of 1.08. The company has a 50 day moving average of $3.73 and a 200-day moving average of $3.54.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Zacks Research raised OraSure Technologies to a “hold” rating in a research note on Friday, October 2nd. Craig Hallum raised OraSure Technologies to a “strong-buy” rating in a research note on Friday, October 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of OraSure Technologies in a report on Tuesday, September 1st. Finally, Wall Street Zen upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, OraSure Technologies currently has an average rating of “Hold” and a consensus target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows.

Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.